ArticleCell death & disease2026

Ferroptosis vulnerability of enzalutamide resistant prostate cancer conferred by ACSL4 overexpression and GPX4 antagonism.

Yi Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.